Seegene's advanced technology for the simultaneous detection and quantification of multiple pathogens is both unique and superior, having already exceeded the capabilities of traditional diagnostic methods. This innovative approach allows for the concurrent identification of the causative agents of various infectious diseases, even in cases of co-infections, genetic variations, and varying levels of infection. Such capabilities are invaluable for the effective monitoring and management of patients' health conditions.

Compact centrifugal microfluidic device designed for point-of-care testing -

Whole blood immunoassays require no sample preparation -

A maximum of three tests per disc, with results available in less than 20 minutes -

Clinically relevant performance according to IFCC classification -

Various connectivity alternatives -

FLAER for PNH

Paroxysmal nocturnal hemoglobinuria (PNH) is a condition characterized by an acquired defect in hematopoietic stem cells, with an annual incidence rate of 1.3 cases per million people. In clinical laboratories, FLAER is employed for multi-parameter flow cytometry, alongside various antibodies such as CD45, CD33, CD24, CD15, and CD14, to identify PNH clones (cells lacking FLAER) within the monocyte and granulocyte lineages.

This approach results in a highly sensitive and accurate test that can be utilized in conjunction with the CD55/CD59 assay to detect PNH clones in red blood cells.

FLAER (Alexa 488 proaerolysin variant) solid format-IVD